Therapeutic composition with a botulinum neurotoxin

Patent metadata

Field	Value
Publication number	US-10105421-B2
Application number	US-201514950587-A
Country	US
Kind code	B2
Filing date	Nov 24, 2015
Priority date	Jul 26, 2004
Publication date	Oct 23, 2018
Grant date	Oct 23, 2018

Abstract

The present invention pertains to pharmaceutical compositions which comprise botulinum toxin from Clostridium botulinum . The pharmaceutical compositions of the instant invention are not only free of a mammalian derived proteinaceous stabilizing agent but are free of any stabilizing protein.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising botulinum toxin complexes from Clostridium botulinum of type A, B, C1, D, E, F or G or a mixture of two or more Clostridium botulinum toxin types, a non-proteinaceous stabilizing agent selected from hyaluronic acid, polyvinylpyrrolidone and polyethyleneglycol, in an amount effective to retain the potency of the botulinum toxin complexes and, optionally, a pH buffer and/or a cryoprotectant, wherein the pharmaceutical composition is free of any stabilizing protein.

2. The pharmaceutical composition of claim 1 , which comprises a pH buffer.

3. The pharmaceutical composition of claim 2 , wherein the pH buffer is sodium acetate.

4. The pharmaceutical composition of claim 1 , which comprises a cryoprotectant.

5. The pharmaceutical composition of claim 4 , wherein the cryoprotectant is a polyalcohol.

6. The pharmaceutical composition of claim 5 , wherein the polyalcohol is selected from one or more of inositol, mannitol, and sorbitol.

7. The pharmaceutical composition of claim 4 , wherein the non-proteinaceous stabilizing agent is hyaluronic acid, and wherein the composition is freeze-dried.

8. A method for stabilizing botulinum toxin complexes from Clostridium botulinum of type A, B, C1, D, E, F or G or a mixture of two or more Clostridium botulinum toxin types, comprising intermixing the botulinum toxin complexes with a non-proteinaceous stabilizing agent selected from hyaluronic acid, polyvinylpyrrolidone and polyethylene glycol, in an aqueous solution in an amount effective to retain the potency of the botulinum toxin complexes in the aqueous solution, wherein the aqueous solution does not comprise any stabilizing protein.

9. The method of claim 8 , wherein the aqueous solution comprises a pH buffer.

10. The method of claim 9 , wherein the pH buffer is sodium acetate.

11. The method of claim 8 , wherein the aqueous solution comprises a cryoprotectant.

12. The method of claim 11 , wherein the aqueous solution is freeze-dried.

13. The method of claim 11 , wherein the non-proteinaceous stabilizing agent is hyaluronic acid and wherein the aqueous solution is freeze-dried.

14. A method of treating a condition for which botulinum toxin therapy or treatment is indicated, comprising the step of administering to a human, or animal in need thereof, a composition comprising botulinum toxin complexes from Clostridium botulinum of type A, B, C1, D, E, F or G or a mixture of two or more Clostridium botulinum toxin types admixed with a non-proteinaceous stabilizing agent, selected from hyaluronic acid, polyvinylpyrrolidone and polyethylene glycol, which non-proteinaceous stabilizing agent is present in an amount effective to retain to potency of the botulinum toxin complexes in an aqueous solution, wherein the aqueous solution does not comprise any stabilizing protein.

15. The method of claim 14 , wherein the composition is administered to an animal, including a human, in an amount effective for the treatment of a condition for which botulinum toxin therapy or treatment is indicated.

16. The method of claim 15 , wherein the condition for which botulinum toxin therapy or treatment is indicated is selected from cosmetic conditions, blepharospasm, hemifacial spasms, spasmodic torticollis, spasticities, dystonias, migraine, low back pain, cervical spine disorders, strabismus, hyperhidrosis and hypersalivation.

17. The method of claim 16 , wherein the cosmetic condition is pronounced wrinkling.

Assignees

• Merz Pharma Gmbh & Co Kgaa

Inventors

• Taylor Harold Victor

Classifications

• A61P27/02

  Ophthalmic agents · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/06

  Antimigraine agents · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title